help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jakub, J. W.
Right arrow Articles by Reintgen, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jakub, J. W.
Right arrow Articles by Reintgen, D. S.
The Oncologist, Vol. 8, No. 1, 59–68, February 2003
© 2003 AlphaMed Press


ORIGINAL PAPER
IMAGING AND DIAGNOSTICS

Current Status of Sentinel Lymph Node Mapping and Biopsy: Facts and Controversies

James W. Jakub, Solange Pendas, Douglas S. Reintgen

The Lakeland Regional Cancer Center, Lakeland, Florida, USA

Correspondence: James W. Jakub, M.D., Lakeland Regional Cancer Center, 300 Parkview Place, Lakeland, Florida 33804, USA. Telephone: 863-603-6565; Fax: 863-603-6576; e-mail: jim.jakub{at}lrmc.com

Lymphatic mapping and sentinel lymph node biopsy were first reported in 1977 by Cabanas for penile cancer. Since that time, the technique has become rapidly assimilated into clinical practice. Morton first described the application of lymphatic mapping for melanoma only a decade ago, and this technique is now accepted as the standard of care. The application for lymphatic mapping and sentinel lymph node biopsy in breast cancer remains approximately 5 years behind its utilization in melanoma. This technique has the potential to be utilized in all solid tumors. The rapid assent of this technique in clinical practice is the result of multiple factors, including accuracy, decreased morbidity, and supplying the pathologist with only a few nodes to allow a more focused and sensitive pathologic evaluation. Despite the success and acceptance of lymphatic mapping, many controversies remain. We have attempted to clearly highlight these controversies in this review.

Key Words. Lymphatic mapping • Sentinel lymph node biopsy • Breast cancer • Melanoma • Colon cancer




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
E. G. Soltesz, S. Kim, R. G. Laurence, A. M. DeGrand, C. P. Parungo, D. M. Dor, L. H. Cohn, M. G. Bawendi, J. V. Frangioni, and T. Mihaljevic
Intraoperative Sentinel Lymph Node Mapping of the Lung Using Near-Infrared Fluorescent Quantum Dots
Ann. Thorac. Surg., January 1, 2005; 79(1): 269 - 277.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. L. Wahl, B. A. Siegel, R. E. Coleman, and C. G. Gatsonis
Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group
J. Clin. Oncol., January 15, 2004; 22(2): 277 - 285.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2003 by AlphaMed Press.